Figure 2 Nonmalignant tissue can be spared from radiation

Slides:

Advertisements

Similar presentations

The TrueBeam System ™ Clinic Name Presenter’s name Clinic location

Advertisements

Radiotherapy for Brain Tumours What do I need to know? Dr Matthew Foote Radiation Oncologist Princess Alexandra Hospital Queensland.

Part 1 Introduction to Radiotherapy and External Beam Radiation Deepak Khuntia, MD Vice President, Medical Affairs Varian Medical Systems.

Volumetric Modulated Arc Therapy (VMAT)

The Health Roundtable 1-1b_HRT1215-Session_HEGI_JOHNSON_WESTMEAD_NSW Volumetric Modulated Arc Therapy for Stereotactic Body Radiotherapy in Early Lung.

Measurement of Dose to Critical Structures Surrounding the Prostate from Intensity-Modulated Radiation Therapy (IMRT) and Three Dimensional Conformal Radiation.

Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):

Cancer.orgPredict Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung.

Modern Radiation Oncology

Copyright © 2012 American Medical Association. All rights reserved.

Figure 1. (a) Dose distribution of dynamic conformal photon therapy

Tumour-Targeted Treatment Intensification for Prostate Cancer Using Magnetic Resonance Imaging Guidance Jessy Abed, RTT, MHScMRS, Jenny Lee, MMath, Tim.

CONTACT Catalina A. Riley

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Concept of the therapeutic index

Insert tables Insert figure

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Radiation Therapy (IMRT) for Anal Carcinoma Heather Ortega, BSRT(T), CMD, Kerry Hibbitts,

Insert tables Insert graphs Insert figure

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Double opposed-field irradiation of an idealized geometry

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Volume 68, Issue 4, Pages (October 2015)

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 1 Cost of one month of treatment with

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 The biological effects of charged particles

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 Algorithm for the determination of the clinical

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Dosimetric comparison of LDR‑BT versus HDR‑BT

Figure 1 NIR fluorescence is more suitable for

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Variations between planned and delivered doses of radiation

Figure 2 The evolution of brachytherapy for prostate cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Advantages of intensity modulated proton therapy during hippocampal avoidance whole brain radiation therapy Joshua Stoker, Sujay Vora, Ameet Patel, David.

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? Georgios Ntentas, DPhil, Katerina Dedeckova, MD, Michal.

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Craniospinal irradiation proton therapy for medulloblastoma

Figure 3 Target volume definitions

Figure 3 Determination of the primary site

Constantinos Zamboglou, Matthias Eiber, Thomas R

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

Presentation transcript:

Figure 2 Nonmalignant tissue can be spared from radiation from charged particles owing to the physical properties of these particles Figure 2 | Nonmalignant tissue can be spared from radiation from charged particles owing to the physical properties of these particles. The treatment plan shown represents a hypofractionated planning target volume dose prescription of 36.25 Gy to be administered in five fractions to a patient with prostate cancer, with a simultaneous integrated boost to the prostate gland of 40 Gy. a | 4-field ProBeam (Varian Medical Systems, Palo Alto, California, USA) proton plan delivered as intensity modulated proton therapy. b | TrueBeam (Varian Medical Systems) photon plan delivered using two nonplanar volumetric arcs (X-ray-based volumetric arc therapy). Both plans delivered the same target dose, but the integral dose delivered was much lower with protons than with X-rays, and the rectum, the main organ at risk with this treatment, was largely spared from radiation. The plan shown in panel b was designed by Anthony Magliari (Varian) and awarded the top scoring in the 2016 American Association of Medical Dosimetrists and Radiosurgery Society Plan Study. Image courtesy of Dr Anthony Magliari. Image courtesy of Dr Anthony Magliari. Durante, M. et al. (2017) Charged-particle therapy in cancer: clinical uses and future perspectives Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.30